Genprex advances diabetes gene therapy GPX-002 into T2D preclinical studies, plans FDA meeting Q1 2026

Genprex, Inc.

Initiated preclinical research in Type 2 diabetic animal models; in vivo proof-of-concept showed normalized glucose levels.
Submitted meeting request to FDA for Q1 2026 to discuss IND-enabling studies for GPX-002.
Transferred GPX-002 manufacturing to experienced CDMO; plans clinical-scale cGMP production.
Continuing construct optimization for second-generation GPX-002 using non-viral lipid nanoparticle delivery.
Toxicology studies to follow FDA interaction; data expected to enable IND filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.